Overview

Safety and Preliminary Effectiveness Study of Mesenchymal Stem Cells, HeXell-2020, in Patients With Stable Coronary Artery Disease

Status:
NOT_YET_RECRUITING
Trial end date:
2028-07-31
Target enrollment:
Participant gender:
Summary
This is a phase I/IIa study to investigate the safety, tolerability, and preliminary effectiveness of HeXell-2020 in patients with stable coronary artery disease (CAD). HeXell-2020 is an investigational drug product consisting of allogenic umbilical cord mesenchymal stem cells (UCMSCs) as the drug substance. All enrolled and eligible subjects will receive HeXell-2020 treatment.
Phase:
PHASE1
Details
Lead Sponsor:
Hexun Biosciences Co., LTD.